Dr. Efrat Dotan, MD

Dr. Dotan practices at Penn Medicine Lancaster General Health Physicians Hematology &Oncology in Lancaster, Pennsylvania.

Dr. Dotan's NPI, 1740312990, was assigned on March 12, 2007. Dr. Dotan holds Pennsylvania license MD433159.

Dr. Dotan's primary practice is Penn Medicine Lancaster General Health Physicians Hematology &Oncology, at 2102 Harrisburg Pike, Lancaster, PA 17601 in Lancaster County. The practice phone is (717) 544-9400.

Dr. Dotan's primary practice is Penn Medicine Lancaster General Health Physicians Hematology &Oncology in Lancaster, Pennsylvania. Dr. Dotan is also affiliated with Lancaster General Hospital. The medical group on file is Penn Medicine Lancaster General Health Physicians, Behavioral Health. Dmand AI also links Dr. Dotan to 1 more hospital, 1 group practice or clinic and 1 medical group, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Dotan practices, 3 sites in all. Vendor and product names are available with a free account.

Medical oncology is Dr. Dotan's primary specialty in the NPI Registry, under taxonomy code 207RX0202X. Dr. Dotan is licensed in Pennsylvania.

CMS data shows 302 Medicare services from Dr. Dotan across 2 procedure codes in 2024, all of them office visits, for 93 Medicare patients. Medicare paid $27,179 for them.

CMS counts 93 Medicare patients who saw Dr. Dotan in 2024. The largest group is 65 to 74, with 45 patients. 75% of them have high blood pressure, and 75% have high cholesterol. 16% are also on Medicaid. Their average risk score is 2.68, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Dotan's median patient age at 69, with 57% women.

In 2024, Dr. Dotan wrote 225 Medicare Part D claims for 58 patients. 76% of them were for generic drugs. CMS names the drug for 71 of them, across 5 drugs with 11 or more claims each, at $10,829 in total drug cost. In 2023, CMS named 130 claims across 8 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 81 out of 100 for Dr. Dotan for performance year 2024, reported as part of a group. Dr. Dotan accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Dotan as offering telehealth.

Dmand AI links 15 papers to Dr. Dotan, published from 2023 to 2025. 2024 was the busiest year, with 9. The most frequent topics are Colonic Neoplasms, Medical Oncology and Pancreatic Neoplasms. Dr. Dotan has published most often in J Palliat Med. Dr. Dotan's most frequent co-authors are Joshua E. Meyer, MD, Sanjay Reddy, MD and Jessica R. Bauman, MD.

CMS Open Payments shows 62 general payments to Dr. Dotan from 16 drug and device companies from 2016 to 2025. Speaker and faculty fees make up the largest share, 75% of the total. Pfizer Inc. paid the most, $109,983. It also lists 2 research payments totaling $3,800 in 2023.